$29.61
0.180.61%
At close: -
$29.61
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Harmony Biosciences Hldgs Analyst Ratings and Price Targets | NASDAQ:HRMY | Benzinga
Harmony Biosciences Holdings Inc has a consensus price target of $50 based on the ratings of 14 analysts. The high is $70 issued by HC Wainwright & Co. on April 8, 2025. The low is $28 issued by Goldman Sachs on January 9, 2024. The 3 most-recent analyst ratings were released by Needham, HC Wainwright & Co., and Needham on April 10, 2025, April 8, 2025, and April 8, 2025, respectively. With an average price target of $56.67 between Needham, HC Wainwright & Co., and Needham, there's an implied 91.38% upside for Harmony Biosciences Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
HC Wainwright & Co.
Mizuho
Deutsche Bank
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Harmony Biosciences Hldgs
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/10/2025 | Buy Now | 68.86% | Needham | Ami Fadia53% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2025 | Buy Now | 136.41% | HC Wainwright & Co. | Patrick Trucchio45% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2025 | Buy Now | 68.86% | Needham | Ami Fadia53% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2025 | Buy Now | 48.6% | Mizuho | Graig Suvannavejh50% | $42 → $44 | Maintains | Outperform | Get Alert |
| 02/27/2025 | Buy Now | 136.41% | HC Wainwright & Co. | Patrick Trucchio45% | $75 → $70 | Maintains | Buy | Get Alert |
| 02/26/2025 | Buy Now | 68.86% | Needham | Ami Fadia53% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/25/2025 | Buy Now | 68.86% | Needham | Ami Fadia53% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2025 | Buy Now | 41.84% | Mizuho | Graig Suvannavejh50% | $52 → $42 | Maintains | Outperform | Get Alert |
| 02/19/2025 | Buy Now | 153.29% | HC Wainwright & Co. | Patrick Trucchio45% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 02/19/2025 | Buy Now | 68.86% | Needham | Ami Fadia53% | $52 → $50 | Maintains | Buy | Get Alert |
| 02/11/2025 | Buy Now | 85.75% | Deutsche Bank | David Hoang35% | → $55 | Initiates | → Buy | Get Alert |
| 01/27/2025 | Buy Now | 153.29% | HC Wainwright & Co. | Patrick Trucchio45% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 01/16/2025 | Buy Now | 153.29% | HC Wainwright & Co. | Patrick Trucchio45% | $75 → $75 | Reiterates | Buy → Buy | Get Alert |
| 01/13/2025 | Buy Now | 75.62% | Needham | Ami Fadia53% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 12/17/2024 | Buy Now | 153.29% | HC Wainwright & Co. | Patrick Trucchio45% | → $75 | Initiates | → Buy | Get Alert |
| 10/30/2024 | Buy Now | 95.88% | Cantor Fitzgerald | Charles Duncan68% | $51 → $58 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | 99.26% | Oppenheimer | Francois Brisebois41% | $56 → $59 | Reiterates | Outperform → Outperform | Get Alert |
| 10/30/2024 | Buy Now | 75.62% | Needham | Ami Fadia53% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 10/29/2024 | Buy Now | 75.62% | Needham | Ami Fadia53% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 10/10/2024 | Buy Now | 35.09% | Raymond James | Danielle Brill42% | → $40 | Reinstates | → Outperform | Get Alert |
| 10/10/2024 | Buy Now | 75.62% | Mizuho | Graig Suvannavejh50% | $42 → $52 | Maintains | Outperform | Get Alert |
| 10/02/2024 | Buy Now | 75.62% | Needham | Ami Fadia53% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 09/24/2024 | Buy Now | 75.62% | Needham | Ami Fadia53% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2024 | Buy Now | 75.62% | Needham | Ami Fadia53% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 09/10/2024 | Buy Now | 89.13% | UBS | Ashwani Verma42% | → $56 | Initiates | → Buy | Get Alert |
| 08/08/2024 | Buy Now | 75.62% | Needham | Ami Fadia53% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 08/06/2024 | Buy Now | 75.62% | Needham | Ami Fadia53% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 06/25/2024 | Buy Now | 75.62% | Needham | Ami Fadia53% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | 75.62% | Needham | Ami Fadia53% | $52 → $52 | Reiterates | Buy → Buy | Get Alert |
| 06/21/2024 | Buy Now | 62.11% | Citigroup | David Hoang35% | → $48 | Initiates | → Buy | Get Alert |
| 05/01/2024 | Buy Now | 75.62% | Needham | Ami Fadia53% | $50 → $52 | Maintains | Buy | Get Alert |
| 04/30/2024 | Buy Now | 68.86% | Needham | Ami Fadia53% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/12/2024 | Buy Now | 65.48% | Cantor Fitzgerald | Charles Duncan68% | $49 → $49 | Reiterates | Overweight → Overweight | Get Alert |
| 04/11/2024 | Buy Now | 68.86% | Needham | Ami Fadia53% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 68.86% | Needham | Ami Fadia53% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | Buy Now | 65.48% | Cantor Fitzgerald | Charles Duncan68% | $49 → $49 | Reiterates | Overweight → Overweight | Get Alert |
| 02/27/2024 | Buy Now | 35.09% | Mizuho | Graig Suvannavejh50% | $42 → $40 | Maintains | Buy | Get Alert |
| 02/23/2024 | Buy Now | 65.48% | Cantor Fitzgerald | Charles Duncan68% | $49 → $49 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | 68.86% | Needham | Ami Fadia53% | $53 → $50 | Maintains | Buy | Get Alert |
| 02/22/2024 | Buy Now | 78.99% | Needham | Ami Fadia53% | $53 → $53 | Reiterates | Buy → Buy | Get Alert |
| 02/16/2024 | Buy Now | 41.84% | Mizuho | Graig Suvannavejh50% | $33 → $42 | Maintains | Buy | Get Alert |
| 01/09/2024 | Buy Now | -5.44% | Goldman Sachs | Corinne Jenkins48% | $25 → $28 | Maintains | Sell | Get Alert |
| 01/02/2024 | Buy Now | 1.32% | B of A Securities | Jason Gerberry59% | → $30 | Downgrade | Neutral → Underperform | Get Alert |
| 11/01/2023 | Buy Now | 78.99% | Needham | Ami Fadia53% | → $53 | Reiterates | Buy → Buy | Get Alert |
| 11/01/2023 | Buy Now | -8.81% | Raymond James | Danielle Brill42% | $26 → $27 | Maintains | Outperform | Get Alert |
| 10/16/2023 | Buy Now | 41.84% | Piper Sandler | David Amsellem70% | $72 → $42 | Maintains | Overweight | Get Alert |
| 10/16/2023 | Buy Now | 78.99% | Needham | Ami Fadia53% | $66 → $53 | Maintains | Buy | Get Alert |
| 10/16/2023 | Buy Now | -12.19% | Raymond James | Danielle Brill42% | $58 → $26 | Maintains | Outperform | Get Alert |
| 10/04/2023 | Buy Now | 82.37% | Mizuho | Graig Suvannavejh50% | → $54 | Reiterates | Buy → Buy | Get Alert |
| 09/26/2023 | Buy Now | 4.69% | Goldman Sachs | Corinne Jenkins48% | $40 → $31 | Maintains | Sell | Get Alert |
| 09/25/2023 | Buy Now | 4.69% | Goldman Sachs | Corinne Jenkins48% | $40 → $31 | Downgrade | Neutral → Sell | Get Alert |
| 09/22/2023 | Buy Now | 122.9% | Needham | Ami Fadia53% | → $66 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2023 | Buy Now | 82.37% | Mizuho | Graig Suvannavejh50% | $54 → $54 | Maintains | Buy | Get Alert |
| 09/07/2023 | Buy Now | 99.26% | Berenberg | Caroline Palomeque60% | → $59 | Initiates | → Buy | Get Alert |
| 08/29/2023 | Buy Now | 82.37% | Mizuho | Graig Suvannavejh50% | → $54 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | Buy Now | 153.29% | Cantor Fitzgerald | Charles Duncan68% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 08/15/2023 | Buy Now | 122.9% | Needham | Ami Fadia53% | → $66 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | Buy Now | 82.37% | Mizuho | Graig Suvannavejh50% | $60 → $54 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | 122.9% | Needham | Ami Fadia53% | → $66 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 95.88% | Raymond James | Danielle Brill42% | $62 → $58 | Maintains | Outperform | Get Alert |
| 08/01/2023 | Buy Now | 122.9% | Needham | Ami Fadia53% | → $66 | Reiterates | Buy → Buy | Get Alert |
| 06/23/2023 | Buy Now | 153.29% | Cantor Fitzgerald | Charles Duncan68% | $75 → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 06/02/2023 | Buy Now | 126.27% | Needham | Ami Fadia53% | → $67 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2023 | Buy Now | 126.27% | Needham | Ami Fadia53% | → $67 | Reiterates | → Buy | Get Alert |
| 05/26/2023 | Buy Now | 133.03% | Oppenheimer | Francois Brisebois41% | → $69 | Reiterates | Outperform → Outperform | Get Alert |
| 05/03/2023 | Buy Now | 153.29% | Cantor Fitzgerald | Charles Duncan68% | $71 → $75 | Maintains | Overweight | Get Alert |
| 05/03/2023 | Buy Now | 126.27% | Needham | Ami Fadia53% | → $67 | Reiterates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | 18.2% | B of A Securities | Jason Gerberry59% | → $35 | Initiates | → Neutral | Get Alert |
| 04/17/2023 | Buy Now | 126.27% | Needham | Ami Fadia53% | → $67 | Reiterates | → Buy | Get Alert |
| 03/30/2023 | Buy Now | 102.63% | Mizuho | Graig Suvannavejh50% | → $60 | Reiterates | → Buy | Get Alert |
| 03/29/2023 | Buy Now | 102.63% | Mizuho | Graig Suvannavejh50% | → $60 | Reiterates | → Buy | Get Alert |
| 02/23/2023 | Buy Now | 45.22% | Goldman Sachs | Corinne Jenkins48% | $49 → $43 | Maintains | Neutral | Get Alert |
| 02/22/2023 | Buy Now | 45.22% | Goldman Sachs | Corinne Jenkins48% | $49 → $43 | Maintains | Neutral | Get Alert |
| 02/22/2023 | Buy Now | 102.63% | Mizuho | Graig Suvannavejh50% | $70 → $60 | Maintains | Buy | Get Alert |
| 02/22/2023 | Buy Now | 126.27% | Needham | Ami Fadia53% | $70 → $67 | Maintains | Buy | Get Alert |
| 02/21/2023 | Buy Now | 136.41% | Needham | Ami Fadia53% | → $70 | Reiterates | → Buy | Get Alert |
| 01/04/2023 | Buy Now | 136.41% | Piper Sandler | David Amsellem70% | $62 → $70 | Maintains | Overweight | Get Alert |
| 11/08/2022 | Buy Now | 136.41% | Mizuho | Graig Suvannavejh50% | $60 → $70 | Maintains | Buy | Get Alert |
| 11/03/2022 | Buy Now | 109.39% | Raymond James | Danielle Brill42% | $60 → $62 | Maintains | Outperform | Get Alert |
| 11/02/2022 | Buy Now | 119.52% | Needham | Ami Fadia53% | $60 → $65 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | 72.24% | Goldman Sachs | Corinne Jenkins48% | $58 → $51 | Maintains | Neutral | Get Alert |
| 10/14/2022 | Buy Now | 106.01% | Jefferies | Chris Howerton63% | $57 → $61 | Upgrade | Hold → Buy | Get Alert |
| 08/04/2022 | Buy Now | 102.63% | Mizuho | Graig Suvannavejh50% | $64 → $60 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | 126.27% | Oppenheimer | Francois Brisebois41% | $62 → $67 | Maintains | Outperform | Get Alert |
| 08/03/2022 | Buy Now | 92.5% | Jefferies | Chris Howerton63% | → $57 | Downgrade | Buy → Hold | Get Alert |
| 08/03/2022 | Buy Now | 102.63% | Raymond James | Danielle Brill42% | $58 → $60 | Maintains | Outperform | Get Alert |
| 07/13/2022 | Buy Now | 85.75% | Goldman Sachs | Corinne Jenkins48% | → $55 | Downgrade | Buy → Neutral | Get Alert |
| 07/07/2022 | Buy Now | 116.14% | Mizuho | Graig Suvannavejh50% | → $64 | Initiates | → Buy | Get Alert |
| 06/29/2022 | Buy Now | 109.39% | Oppenheimer | Francois Brisebois41% | $55 → $62 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Harmony Biosciences Hldgs (HRMY) stock?
The latest price target for Harmony Biosciences Hldgs (NASDAQ:HRMY) was reported by Needham on April 10, 2025. The analyst firm set a price target for $50.00 expecting HRMY to rise to within 12 months (a possible 68.86% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Harmony Biosciences Hldgs (HRMY)?
The latest analyst rating for Harmony Biosciences Hldgs (NASDAQ:HRMY) was provided by Needham, and Harmony Biosciences Hldgs reiterated their buy rating.
When was the last upgrade for Harmony Biosciences Hldgs (HRMY)?
The last upgrade for Harmony Biosciences Holdings Inc happened on October 14, 2022 when Jefferies raised their price target to $61. Jefferies previously had a hold for Harmony Biosciences Holdings Inc.
When was the last downgrade for Harmony Biosciences Hldgs (HRMY)?
The last downgrade for Harmony Biosciences Holdings Inc happened on January 2, 2024 when B of A Securities changed their price target from N/A to $30 for Harmony Biosciences Holdings Inc.
When is the next analyst rating going to be posted or updated for Harmony Biosciences Hldgs (HRMY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harmony Biosciences Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harmony Biosciences Hldgs was filed on April 10, 2025 so you should expect the next rating to be made available sometime around April 10, 2026.
Is the Analyst Rating Harmony Biosciences Hldgs (HRMY) correct?
While ratings are subjective and will change, the latest Harmony Biosciences Hldgs (HRMY) rating was a reiterated with a price target of $50.00 to $50.00. The current price Harmony Biosciences Hldgs (HRMY) is trading at is $29.61, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
